Ruta Graveolens Whole

Dosage for Ruta Graveolens Whole is highly individualized and must be determined by a specialist in allergy and immunology. There is no 'standard' dose due to the non-standardized nature of the extract.

Diagnostic Testing

• Skin Prick Test (SPT): One drop of the 1:10 or 1:20 w/v extract is applied to the skin, followed by a superficial puncture. Results are read at 15–20 minutes.
• Intradermal Test: If the SPT is negative, 0.02 mL of a 1:1000 to 1:100 dilution may be injected into the dermis to form a 2-3 mm wheal.

Immunotherapy

• Build-up Phase: Treatment typically begins with a very low dose (e.g., 0.05 mL of a 1:10,000 dilution) administered subcutaneously once or twice weekly. The dose is gradually increased based on patient tolerance.
• Maintenance Phase: Once the target dose is reached (the 'maintenance dose'), injections are typically given every 2 to 4 weeks. The maintenance dose is usually the highest dose the patient can tolerate without significant systemic or local reactions.

Ruta Graveolens Whole extracts may be used in children, but dosage must be calculated with extreme caution. Children are at a higher risk for systemic reactions. Immunotherapy is generally not started in children under the age of 5 due to the difficulty of communicating early symptoms of anaphylaxis. For children over 5, the dosing schedule mirrors the adult build-up phase but may progress more slowly.

Renal Impairment

No specific dosage adjustments are provided for renal impairment, as the systemic absorption of the extract is minimal. However, patients with severe renal disease may have altered cutaneous reactivity, potentially leading to false-negative skin tests.

Hepatic Impairment

No dosage adjustments are required for hepatic impairment. The metabolism of allergenic proteins is not dependent on hepatic CYP450 enzymes.

Elderly Patients

Elderly patients (over 65) may have reduced skin reactivity (atrophy of the skin), which can affect diagnostic accuracy. Furthermore, the risk of cardiovascular complications during an anaphylactic event is significantly higher in this population. Lower starting doses in immunotherapy may be considered.

This medication is NEVER for self-administration. It must be administered by a healthcare professional in a clinical setting equipped to handle anaphylaxis.

• Administration Route: Subcutaneous injection (for immunotherapy) or epicutaneous/intradermal (for testing).
• Observation Period: Patients MUST remain in the clinic for at least 30 minutes following any injection to monitor for systemic reactions.
• Storage: Store vials in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Discard if the solution becomes cloudy or contains precipitates.

In immunotherapy, if a dose is missed:

• Short delay (up to 1 week): The same dose may often be given.
• Moderate delay (2-4 weeks): The dose may need to be reduced to the previous tolerated level.
• Long delay (over 4 weeks): The build-up phase may need to be restarted from a much lower concentration to avoid loss of tolerance.

An 'overdose' in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current threshold of tolerance.

• Signs: Rapid onset of hives (urticaria), swelling of the throat (angioedema), wheezing, shortness of breath, or a drop in blood pressure (hypotension).
• Emergency Measures: Immediate administration of epinephrine (1:1000) intramuscularly, followed by oxygen, IV fluids, and antihistamines as directed by emergency protocols.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or skip appointments without medical guidance.

Most patients receiving Ruta Graveolens Whole will experience some form of localized reaction. These are generally considered part of the body's expected response to the allergen.

• Local Wheal and Flare: Redness and swelling at the site of the skin test or injection. This usually peaks within 20 minutes and subsides within 2-4 hours.
• Injection Site Itching: A persistent 'prickly' or itchy sensation at the site of administration.
• Late-Phase Local Reaction: Swelling and tenderness at the injection site that appears 6 to 12 hours after administration and can last for 24 hours. This is common in the build-up phase of immunotherapy.

• Systemic Urticaria: Hives appearing on parts of the body away from the injection site.
• Nasal Congestion: A 'stuffy' nose or sneezing shortly after administration.
• Fatigue: Some patients report feeling unusually tired for several hours following an immunotherapy injection.
• Contact Dermatitis: Rue is known to contain furocoumarins, which can cause skin irritation or rashes if the extract comes into contact with the skin surface outside of the controlled test area.

• Phytophotodermatitis: Because Ruta graveolens contains photosensitizing compounds (psoralens), exposure to UV light following skin contact with the extract can cause severe blistering or hyperpigmentation.
• Vasovagal Reactions: Fainting or lightheadedness due to the stress of the injection or needle phobia, rather than an allergic response.

> Warning: Stop taking Ruta Graveolens Whole and call your doctor immediately if you experience any of these.

• Anaphylaxis: A life-threatening systemic allergic reaction. Symptoms include a feeling of 'impending doom,' swelling of the tongue, difficulty swallowing, and rapid pulse.
• Bronchospasm: Sudden wheezing or chest tightness, particularly in patients with a history of asthma.
• Hypotension: A dangerous drop in blood pressure that may lead to dizziness or loss of consciousness.
• Laryngeal Edema: Swelling of the throat that obstructs the airway.

With prolonged immunotherapy, the most significant risk is the development of new sensitivities, although this is rare. Long-term use of Ruta graveolens extracts in traditional (non-regulated) settings has been associated with hepatic stress, though this is not typically observed with the micro-doses used in standardized clinical allergenic extracts.

As a Non-Standardized Allergenic Extract, Ruta Graveolens Whole carries a class-wide warning regarding the risk of severe systemic reactions.

WARNING: RISK OF ANAPHYLAXIS

• Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis.
• Do not administer if the patient has severe, unstable, or uncontrolled asthma.
• Observe patients for at least 30 minutes after administration.
• Epinephrine must be immediately available.
• Patients with certain medical conditions (e.g., those on beta-blockers) may be at increased risk and may be less responsive to epinephrine.

Report any unusual symptoms to your healthcare provider immediately. Even a 'mild' systemic reaction should be reported, as it may precede a more severe reaction at the next dose.

Ruta Graveolens Whole is a potent biological product. Its use is restricted to clinicians trained in the diagnosis and treatment of allergic diseases. The primary safety concern is the unpredictable nature of hypersensitivity; a dose that was well-tolerated last week may cause a reaction this week due to changes in the patient's baseline allergic load (e.g., during high pollen seasons or during an illness).

No specific FDA black box warning exists solely for Ruta Graveolens Whole, but it is subject to the general black box warnings for all Allergenic Extracts. These warnings emphasize that extracts should only be used by physicians experienced in their administration and that emergency equipment for the treatment of anaphylaxis must be present.

• Allergic Reactions / Anaphylaxis Risk: This is the most significant risk. Patients must be screened for recent asthma flares or new illnesses before every injection.
• Asthma Status: Patients with symptomatic or poorly controlled asthma are at a significantly higher risk for a fatal reaction. Immunotherapy should be withheld if the patient's Peak Expiratory Flow (PEF) is significantly below their personal best.
• Photosensitivity: Because Ruta graveolens contains furocoumarins, patients should avoid direct sunlight or UV tanning beds on the area of the skin test for at least 24-48 hours to prevent phytophotodermatitis (a chemical skin burn triggered by light).
• Injection Technique: Accidental intravenous injection can lead to immediate systemic reactions. Aspiration before injection is mandatory.

• Pre-Injection Screening: Check for any late-phase reactions from the previous dose and assess current respiratory status.
• Post-Injection Observation: A mandatory 30-minute wait time in the clinic.
• Lung Function: For asthmatic patients, periodic spirometry or peak flow monitoring is recommended to ensure stability during the build-up phase.

Patients generally do not have restrictions on driving or operating machinery unless they experience a systemic reaction or receive sedative medications (like antihistamines) to treat a local reaction. However, if a patient feels lightheaded or 'off' after an injection, they should not drive until symptoms fully resolve.

Alcohol consumption should be avoided on the day of an injection. Alcohol can increase peripheral vasodilation, which may theoretically accelerate the absorption of the allergen or exacerbate the symptoms of a systemic reaction.

If a patient experiences a Grade 3 or 4 systemic reaction (severe bronchospasm or hypotension), the risks of continuing immunotherapy usually outweigh the benefits. Tapering is not required for allergenic extracts, but the decision to stop should be made by an allergist after a thorough risk-benefit analysis.

> Important: Discuss all your medical conditions with your healthcare provider before starting Ruta Graveolens Whole, especially if you have a history of heart disease or severe asthma.

• Beta-Blockers (e.g., Propranolol, Metoprolol): These are generally contraindicated in patients receiving allergenic immunotherapy. Beta-blockers can increase the severity of anaphylaxis and, more importantly, make the patient resistant to the effects of epinephrine, which is the primary treatment for an allergic emergency.

• ACE Inhibitors (e.g., Lisinopril): These may increase the risk of severe systemic reactions or angioedema in patients receiving allergenic extracts.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of sympathomimetic amines used to treat a reaction, leading to hypertensive crisis.
• Tricyclic Antidepressants: Similar to MAOIs, these can interfere with the treatment of an allergic reaction.

• Antihistamines (e.g., Cetirizine, Loratadine): These must be discontinued 3 to 7 days prior to diagnostic skin testing. They suppress the histamine-induced wheal and flare response, leading to false-negative results. They do not, however, need to be stopped for immunotherapy and are often used to manage local reactions.
• H2 Blockers (e.g., Famotidine): These can also modestly suppress skin test results and should be discontinued before testing.
• Topical Corticosteroids: If applied to the test site, these will suppress the inflammatory response and invalidate the skin test.

• High-Fat Meals: There is no direct interaction, but heavy meals immediately before an injection may complicate the assessment of gastrointestinal symptoms of anaphylaxis (e.g., nausea or cramping).
• Caffeine: Excessive caffeine may increase heart rate, potentially complicating the monitoring of a patient's vital signs after an injection.

• St. John's Wort: May increase photosensitivity, which could exacerbate the risk of a reaction to the Ruta graveolens extract if the skin is exposed to sunlight.
• Supplements with Antihistaminic Properties: High doses of Vitamin C or Quercetin may theoretically dampen skin test results, though clinical significance is low.

Ruta Graveolens Whole does not interfere with standard blood chemistry or hematology labs. However, it will directly affect:

• Skin Prick Tests: As intended.
• Serum IgE Testing (ImmunoCAP): Successful immunotherapy will eventually lead to changes in allergen-specific IgE and IgG4 levels, which is a monitored clinical outcome rather than an 'interaction.'

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete list is vital for your safety during allergy testing and treatment.

• Severe Uncontrolled Asthma: Patients with an FEV1 consistently below 70% of predicted or those with recent hospitalizations for asthma should not receive immunotherapy due to the high risk of fatal bronchospasm.
• Recent Myocardial Infarction (Heart Attack): The stress of a potential systemic reaction and the subsequent need for epinephrine can be fatal in patients with unstable cardiovascular disease.
• Hypersensitivity to Extract Components: If a patient has had a prior life-threatening reaction to the specific components of the Ruta extract (other than the intended therapeutic response), it is contraindicated.
• Pregnancy (for starting immunotherapy): Immunotherapy should never be initiated during pregnancy due to the risk of maternal anaphylaxis, which can cause fetal hypoxia and death.

• Beta-Blocker Therapy: While often listed as absolute, some guidelines allow for immunotherapy if no alternative cardiac medication is available, provided the patient is fully informed of the risks.
• Autoimmune Disorders: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may experience a flare of their condition when the immune system is stimulated by immunotherapy.
• Malignancy: Immunotherapy is generally avoided in patients with active cancer as it may theoretically interfere with the body's immune response to the tumor.

Patients allergic to other members of the Rutaceae family (such as citrus fruits, including lemon, orange, and lime) may show cross-reactivity with Ruta Graveolens Whole. Additionally, because this is classified under the Fungal EPC in some contexts, clinicians should be alert for cross-reactivity in patients with known sensitivities to common molds like Alternaria or Cladosporium, although the botanical nature of Ruta makes this less common than family-based cross-reactivity.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Ruta Graveolens Whole.

Ruta Graveolens Whole is generally classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. However, Ruta graveolens (the plant) is historically known as an emmenagogue and abortifacient when consumed in large quantities. While the amounts in allergenic extracts are minute, the risk of anaphylaxis remains the primary concern. Anaphylaxis during pregnancy can lead to uterine contractions, placental abruption, and fetal distress. Immunotherapy doses should not be increased during pregnancy, though maintenance doses may be continued if the benefit outweighs the risk.

It is not known whether the allergenic components of Ruta Graveolens Whole are excreted in human milk. Because these are large proteins that are likely degraded in the infant's digestive tract, the risk to the nursing infant is considered low. The primary concern remains the mother's potential for a systemic reaction.

Safety and effectiveness in children under the age of 5 have not been established. In older children, Ruta Graveolens Whole is used for diagnostic purposes. When used for immunotherapy, children must be monitored closely, as they may not be able to articulate early symptoms of a reaction, such as an 'itchy throat' or 'funny taste in the mouth.'

Clinical studies of allergenic extracts did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of concomitant diseases (especially cardiac and respiratory) and other drug therapies (like beta-blockers).

There is no evidence that renal impairment affects the safety or efficacy of Ruta Graveolens Whole. However, clinicians should be aware that patients with end-stage renal disease may have blunted skin test responses due to uremia.

Hepatic impairment does not affect the pharmacokinetics of allergenic extracts. No dose adjustment is required, but the patient's overall health status should be stable before beginning a course of immunotherapy.

> Important: Special populations require individualized medical assessment. Always inform your specialist of any changes in your health status, including pregnancy.

Ruta Graveolens Whole functions as a concentrated source of allergens. In the diagnostic phase, it acts as a 'provocative' agent. Upon introduction into the skin, the allergens bind to specific IgE antibodies on the surface of mast cells. This triggers the release of pre-formed mediators like histamine. In the therapeutic phase (immunotherapy), the mechanism is complex and involves:

1. 1Desensitization: Immediate reduction in mast cell and basophil reactivity.
2. 2T-cell Tolerance: Induction of T-regulatory cells that produce IL-10 and TGF-beta.
3. 3Antibody Switching: A decrease in allergen-specific IgE and a long-term increase in allergen-specific IgG4.

• Onset of Action (Diagnostic): 15–20 minutes for a wheal and flare response.
• Onset of Action (Therapeutic): 6–12 months of immunotherapy are typically required before significant symptom reduction is noted.
• Duration of Effect: Diagnostic effects last only a few hours. Therapeutic effects can persist for 3–5 years or longer after completing a full course (3–5 years) of immunotherapy.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Local/Subcutaneous) |

| Protein Binding | Primarily to IgE/IgG4 |

| Half-life | Proteins degraded within hours |

| Tmax | 15-30 mins (Local response) |

| Metabolism | Proteolysis |

| Excretion | Renal (as peptides) |

• Source: Whole plant of Ruta graveolens.
• Key Constituents: Rutin (a flavonoid), furocoumarins (psoralen, xanthotoxin, bergapten), and various alkaloids (arborinine).
• Solubility: Soluble in aqueous buffers or glycerin-saline solutions.
• Molecular Weight: Variable (mixture of allergenic proteins ranging from 10 to 70 kDa).

Ruta Graveolens Whole is classified as a Non-Standardized Fungal Allergenic Extract [EPC]. It is part of a broader group of biologicals used for 'In Vivo Diagnostic Biological Aid' and 'Allergenic Immunotherapy.' It is related to other botanical extracts like Ragweed or Grass Pollen extracts, though its specific chemical profile (rich in rutin and psoralens) is unique.